09639400600

Saturday To Thursday 9 am To 6 pm
butwwbuttw

Sitagliptin

  Refine Search
Filter on Price
Filter on Discount
  Featured
  Featured


Glipita 100 tablet

Glipita 100 tablet

Glipita is the preparation of Sitagliptin. Sitagliptin is a new oral agent approved by the USFDA to treat type 2 diabetes with diet & exercise. It belongs to a new class of antihyperglycemic, Dipeptidyl Dipeptidase-4 (DPP-4) inhibitors. This unique class of orally active agent targets the underlying pathophysiologic processes of type 2 diabetic patients and provides an excellent alternative to the traditional agents...

Tk.25.00/=

  0 отзывов

Glipita 50 tablet

Glipita 50 tablet

Glipita 50 tablet..

Tk.13.01/=

  0 отзывов

Glucodip-MXR 1000

Glucodip-MXR 1000

Glucodip-M XR 1000..

Tk.22.00/=

  0 отзывов

Glucodip-MXR 500

Glucodip-MXR 500

Glucodip-M XR 500..

Tk.20.00/=

  0 отзывов

Incrit 100 mg Tab

Incrit 100 mg Tab

Incrit 100 mg Tab..

Tk.30.00/=

  0 отзывов

Incrit 50 mg Tab

Incrit 50 mg Tab

Incrit 50 mg Tab..

Tk.18.05/=

  0 отзывов

Incrit-M 1000 Tab

Incrit-M 1000 Tab

Incrit-M 1000 Tab..

Tk.22.07/=

  0 отзывов

Janvia 100 Tab

Janvia 100 Tab

..

Tk.28.08/=

  0 отзывов

Janvia 50 Tab

Janvia 50 Tab

..

Tk.15.04/=

  0 отзывов

SGN 50

SGN 50

SGN 50..

Tk.15.00/=

  0 отзывов

Siglita 100 tablet

Siglita 100 tablet

Indication: SiglitaTM is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.Dosage & Administration:The recommended dose of SiglitaTM is 100 mg once daily. SiglitaTM can be taken with or without food. For patients with mild renal insufficiency (creatinine clearance [CrCl] 50 mL/min) no dosage adjustment for SiglitaTM is required. For patients with moderate renal insufficiency (CrCl 30 to <50 mL/min), the dose of SiglitaTM is 50 mg once daily. For patients with severe renal insufficiency (CrCl <30 mL/min) or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, the dose of SiglitaTM is 25 mg once daily. SiglitaTMmay be administered without regard to the timing of hemodialysis...

Tk.30.10/=

  0 отзывов

Siglita 50 tablet

Siglita 50 tablet

Indication: SiglitaTM is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.Dosage & Administration:The recommended dose of SiglitaTM is 100 mg once daily. SiglitaTM can be taken with or without food. For patients with mild renal insufficiency (creatinine clearance [CrCl] 50 mL/min) no dosage adjustment for SiglitaTM is required. For patients with moderate renal insufficiency (CrCl 30 to <50 mL/min), the dose of SiglitaTM is 50 mg once daily. For patients with severe renal insufficiency (CrCl <30 mL/min) or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, the dose of SiglitaTM is 25 mg once daily. SiglitaTM may be administered without regard to the timing of hemodialysis...

Tk.18.05/=

  0 отзывов

Sigtil

Sigtil

Sigtil..

Tk.14.82/=

  0 отзывов

Silinor 100 mg Tablet

Silinor 100 mg Tablet

Silinor 100 mg Tablet..

Tk.48.00/=

  0 отзывов

Silinor 25 mg Tablet

Silinor 25 mg Tablet

Silinor 25 mg Tablet..

Tk.10.00/=

  0 отзывов

Silinor 50 mg tablet

Silinor 50 mg tablet

Silinor 50 mg tablet..

Tk.18.00/=

  0 отзывов

Silinor- M 50/500 TABLET

Silinor- M 50/500 TABLET

Silinor- M 50/500 TABLET..

Tk.20.00/=

  0 отзывов

Sitagil 100

Sitagil 100

Sitagil 100 TabDescriptionSitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which exerts its action by slowing the inactivation of incretin hormones. Incretin hormones, including glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production.IndicationsSitagil is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Sitagil is indicated as monotherapy and also indicated for use in combination with metformin, sulfonylurea or thiazolidinediones when diet and exercise plus the single agent does not result in adequate glycemic control.Dosage & Administration- The recommended dose of Sitagliptin is 100 mg once daily. Sitagliptin can be taken with or without food.- For patients with mild renal insufficiency ( creatinine clearance [CrCl]>50ml/min), no dosage adjustment is required.- For patients with moderate renal insufficiency ( CrCl.>30 to <50 ml/min women), the dose of Sitagliptin is 50 mg once daily.- For patients with severe renal insufficiency (CrCl<30 ml/min) or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, the dose of Sitagliptin is 25 mg once daily.Pediatric Use:Safety and effectiveness of Sitagliptin in pediatric patients under 18 years of age have not been established.Geriatric Use:No overall differences in safety or effectiveness were observed between subjects over 65 years. The drug is excreted by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in the elderly.Side EffectsAdverse reactions like upper respiratory tract infection, nasopharyngitis, and headache can occur. Hypoglycemia occurs in patients treated with the combination of Sitagliptin and sulfonylurea, with or without Metformin.Precautions- Dosage adjustment is recommended in patients with moderate or severe renal insufficiency and in patients with ESRD.- When used with a sulfonylurea a lower dose of sulfonylurea may be required to reduce the risk of hypoglycemia.Use in Pregnancy & LactationPregnanacy: Safety in pregnant women has not been established. Sitagliptin should be used during pregnancy only if the potential benefit justifies the potential risk of the fetus.Nursing mothers: It is not known whether Sitagliptin is secreted in human milk, it should not be administered to a breast feeding woman.Drug InteractionThere was a slight increase in the area under the curve and mean peak drug concentration of Digoxin with the co-administration of 100 mg Sitagliptin for 10 days.Over DoseIn the event of an overdose, it is reasonable to employ the usual supportivemeasures as dictated by the patient’s clinical status. Sitagliptin is modestly dialyzable. Prolonged hemodialysis may be considered if clinically appropriate...

Tk.28.00/=

  0 отзывов

Sitagil 25

Sitagil 25

Sitagil 25 TabDescriptionSitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which exerts its action by slowing the inactivation of incretin hormones. Incretin hormones, including glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production.IndicationsSitagil is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Sitagil is indicated as monotherapy and also indicated for use in combination with metformin, sulfonylurea or thiazolidinediones when diet and exercise plus the single agent does not result in adequate glycemic control.Dosage & Administration- The recommended dose of Sitagliptin is 100 mg once daily. Sitagliptin can be taken with or without food.- For patients with mild renal insufficiency ( creatinine clearance [CrCl]>50ml/min), no dosage adjustment is required.- For patients with moderate renal insufficiency ( CrCl.>30 to <50 ml/min women), the dose of Sitagliptin is 50 mg once daily.- For patients with severe renal insufficiency (CrCl<30 ml/min) or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, the dose of Sitagliptin is 25 mg once daily.Pediatric Use:Safety and effectiveness of Sitagliptin in pediatric patients under 18 years of age have not been established.Geriatric Use:No overall differences in safety or effectiveness were observed between subjects over 65 years. The drug is excreted by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in the elderly.Side EffectsAdverse reactions like upper respiratory tract infection, nasopharyngitis, and headache can occur. Hypoglycemia occurs in patients treated with the combination of Sitagliptin and sulfonylurea, with or without Metformin.Precautions- Dosage adjustment is recommended in patients with moderate or severe renal insufficiency and in patients with ESRD.- When used with a sulfonylurea a lower dose of sulfonylurea may be required to reduce the risk of hypoglycemia.Use in Pregnancy & LactationPregnanacy: Safety in pregnant women has not been established. Sitagliptin should be used during pregnancy only if the potential benefit justifies the potential risk of the fetus.Nursing mothers: It is not known whether Sitagliptin is secreted in human milk, it should not be administered to a breast feeding woman.Drug InteractionThere was a slight increase in the area under the curve and mean peak drug concentration of Digoxin with the co-administration of 100 mg Sitagliptin for 10 days.Over DoseIn the event of an overdose, it is reasonable to employ the usual supportivemeasures as dictated by the patient’s clinical status. Sitagliptin is modestly dialyzable. Prolonged hemodialysis may be considered if clinically appropriate...

Tk.8.00/=

  0 отзывов

Sitagil 50

Sitagil 50

Sitagil 50 TabDescriptionSitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which exerts its action by slowing the inactivation of incretin hormones. Incretin hormones, including glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production.IndicationsSitagil is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Sitagil is indicated as monotherapy and also indicated for use in combination with metformin, sulfonylurea or thiazolidinediones when diet and exercise plus the single agent does not result in adequate glycemic control.Dosage & Administration- The recommended dose of Sitagliptin is 100 mg once daily. Sitagliptin can be taken with or without food.- For patients with mild renal insufficiency ( creatinine clearance [CrCl]>50ml/min), no dosage adjustment is required.- For patients with moderate renal insufficiency ( CrCl.>30 to <50 ml/min women), the dose of Sitagliptin is 50 mg once daily.- For patients with severe renal insufficiency (CrCl<30 ml/min) or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, the dose of Sitagliptin is 25 mg once daily.Pediatric Use:Safety and effectiveness of Sitagliptin in pediatric patients under 18 years of age have not been established.Geriatric Use:No overall differences in safety or effectiveness were observed between subjects over 65 years. The drug is excreted by the kidney. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in the elderly.Side EffectsAdverse reactions like upper respiratory tract infection, nasopharyngitis, and headache can occur. Hypoglycemia occurs in patients treated with the combination of Sitagliptin and sulfonylurea, with or without Metformin.Precautions- Dosage adjustment is recommended in patients with moderate or severe renal insufficiency and in patients with ESRD.- When used with a sulfonylurea a lower dose of sulfonylurea may be required to reduce the risk of hypoglycemia.Use in Pregnancy & LactationPregnanacy: Safety in pregnant women has not been established. Sitagliptin should be used during pregnancy only if the potential benefit justifies the potential risk of the fetus.Nursing mothers: It is not known whether Sitagliptin is secreted in human milk, it should not be administered to a breast feeding woman.Drug InteractionThere was a slight increase in the area under the curve and mean peak drug concentration of Digoxin with the co-administration of 100 mg Sitagliptin for 10 days.Over DoseIn the event of an overdose, it is reasonable to employ the usual supportivemeasures as dictated by the patient’s clinical status. Sitagliptin is modestly dialyzable. Prolonged hemodialysis may be considered if clinically appropriate...

Tk.15.00/=

  0 отзывов

Sitagil M 100/1000 ER

Sitagil M 100/1000 ER

Sitagil M 100/1000 ER TabDescriptionSitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which exerts its action by slowing the inactivation of incretin hormones. Incretin hormones, including glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. The pharmacologic mechanism of action of Metformin is different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and increases peripheral glucose uptake and utilization.IndicationsSitagliptin + Metformin ER is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Sitagliptin and Metformin extended release is appropriate.Dosage & AdministrationMay adjust the dosing based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of 100 mg Sitagliptin and 2000 mg Metformin extended release.Administer once daily with a meal preferably in the evening. Gradually escalate the dose to reduce the gastrointestinal side effects due to Metformin. Maintain the same total daily dose of Sitagliptin and Metformin when changing between Sitagliptin + Metformin ER, without exceeding the maximum recommended daily dose of 2000 mg Metformin extended release.Swallow whole. Never split, crush or chew.Side Effects• The most common adverse reactions reported in ≥5% of patients simultaneously started on Sitagliptin and Metformin and more commonly than in patients treated with placebo were diarrhea, upper respiratory tract infection, and headache.• Adverse reactions reported in ≥5% of patients treated with Sitagliptin in combination with Sulfonylurea and Metformin and more commonly than in patients treated with placebo in combination with Sulfonylurea and Metformin were hypoglycemia and headache.• Hypoglycemia was the only adverse reaction reported in ≥5% of patients treated with Sitagliptin in combination with insulin and Metformin and more commonly than in patients treated with placebo in combination with insulin and Metformin.PrecautionsDo not use the combination of Sitagliptin & Metformin in patients with hepatic disease. Before initiating the combination and at least annually thereafter, assess renal function and verify as normal. May need to discontinue the combination and temporarily use insulin during periods of stress and decreased intake of fluids and food as may occur with fever, trauma, infection or surgery.Use in Pregnancy & Lactation• There are no adequate and well-controlled studies in pregnant women with Sitagliptin + Metformin ER or its individual components; therefore, the safety of Sitagliptin + Metformin ER in pregnant women is not known. Sitagliptin + Metformin ER should be used during pregnancy only if clearly needed.• It is not known whether Sitagliptin or Metformin are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Sitagliptin + Metformin ER is administered to a nursing woman.Drug InteractionCarbonic anhydrase inhibitors should be used with caution treated with Sitagliptin + Metformin ER, as the risk of lactic acidosis may increase.Careful patient monitoring and dose adjustment of Sitagliptin + Metformin ER and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system.Over DoseSitagliptinThere is no experience with doses above 800 mg in clinical studies. In the event of an overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring (including obtaining an electrocardiogram), and institute supportive therapy as indicated by the patient\\\'s clinical status.Prolonged hemodialysis may be considered if clinically appropriate. It is not known if Sitagliptin is dialyzable by peritoneal dialysis.Metformin HydrochlorideOverdose of Metformin Hydrochloride has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with Metformin Hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of Metformin overdose cas..

Tk.35.00/=

  0 отзывов

Sitap 100 Tab

Sitap 100 Tab

Sitap 100 Tab..

Tk.28.08/=

  0 отзывов

Sitap 50 Tab

Sitap 50 Tab

Sitap 50 Tab..

Tk.15.05/=

  0 отзывов

Sitavia 50

Sitavia 50

Sitavia 50..

Tk.15.00/=

  0 отзывов

Sitavia 50 mg Tab

Sitavia 50 mg Tab

Sitavia 100..

Tk.15.00/=

  0 отзывов

Showing 1 to 25 of 25 (1 Pages)